Edge Therapeutics, Inc. (EDGE) CEO Sells $27,300.00 in Stock
Edge Therapeutics, Inc. (NASDAQ:EDGE) CEO Brian A. Leuthner sold 2,500 shares of the firm’s stock in a transaction on Wednesday, November 1st. The stock was sold at an average price of $10.92, for a total value of $27,300.00. Following the transaction, the chief executive officer now owns 102,736 shares of the company’s stock, valued at $1,121,877.12. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.
Edge Therapeutics, Inc. (NASDAQ:EDGE) traded up $0.02 during trading hours on Friday, reaching $10.75. The company had a trading volume of 60,964 shares, compared to its average volume of 54,795. The company has a quick ratio of 9.43, a current ratio of 8.34 and a debt-to-equity ratio of 0.20.
Edge Therapeutics (NASDAQ:EDGE) last released its earnings results on Wednesday, November 1st. The biotechnology company reported ($0.37) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.48) by $0.11. research analysts anticipate that Edge Therapeutics, Inc. will post -1.9 EPS for the current year.
TRADEMARK VIOLATION WARNING: This piece was first published by American Banking News and is the property of of American Banking News. If you are viewing this piece on another website, it was stolen and reposted in violation of US and international trademark and copyright legislation. The legal version of this piece can be accessed at https://www.americanbankingnews.com/2017/11/03/edge-therapeutics-inc-edge-ceo-sells-27300-00-in-stock.html.
Several research firms have recently commented on EDGE. BidaskClub upgraded Edge Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 3rd. Zacks Investment Research lowered Edge Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, August 3rd.
A number of large investors have recently added to or reduced their stakes in EDGE. Wells Fargo & Company MN boosted its holdings in Edge Therapeutics by 1.7% in the first quarter. Wells Fargo & Company MN now owns 11,942 shares of the biotechnology company’s stock valued at $109,000 after purchasing an additional 200 shares during the period. Vanguard Group Inc. boosted its holdings in Edge Therapeutics by 2.9% in the first quarter. Vanguard Group Inc. now owns 700,003 shares of the biotechnology company’s stock valued at $6,377,000 after purchasing an additional 19,973 shares during the period. Geode Capital Management LLC boosted its holdings in Edge Therapeutics by 5.0% in the first quarter. Geode Capital Management LLC now owns 172,646 shares of the biotechnology company’s stock valued at $1,572,000 after purchasing an additional 8,181 shares during the period. Renaissance Technologies LLC purchased a new position in Edge Therapeutics in the first quarter valued at $297,000. Finally, Schwab Charles Investment Management Inc. boosted its holdings in Edge Therapeutics by 6.8% in the first quarter. Schwab Charles Investment Management Inc. now owns 74,747 shares of the biotechnology company’s stock valued at $681,000 after purchasing an additional 4,788 shares during the period. Hedge funds and other institutional investors own 49.38% of the company’s stock.
Edge Therapeutics Company Profile
Edge Therapeutics, Inc is a clinical-stage biotechnology company that discovers, develops and seeks to commercialize hospital-based therapies capable of transforming treatment paradigms in the management of acute, life-threatening critical care conditions. The Company’s initial product candidates target rare, acute, life-threatening neurological and other conditions.
Receive News & Ratings for Edge Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edge Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.